Earnings results for Amicus Therapeutics (NASDAQ:FOLD)
Amicus Therapeutics, Inc. is expected* to report earnings on 05/10/2021 before market open. The report will be for the fiscal Quarter ending Mar 2021. According to Zacks Investment Research, based on 5 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.23. The reported EPS for the same quarter last year was $-0.35.
Amicus Therapeutics last posted its quarterly earnings data on February 28th, 2021. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.04. The firm earned $70.57 million during the quarter, compared to analysts’ expectations of $70.50 million. Amicus Therapeutics has generated ($1.31) earnings per share over the last year. Amicus Therapeutics has confirmed that its next quarterly earnings report will be published on Monday, May 10th, 2021. Amicus Therapeutics will be holding an earnings conference call on Monday, May 10th. Interested parties can register for or listen to the call using this link.
Analyst Opinion on Amicus Therapeutics (NASDAQ:FOLD)
13 Wall Street analysts have issued ratings and price targets for Amicus Therapeutics in the last 12 months. Their average twelve-month price target is $20.04, predicting that the stock has a possible upside of 108.73%. The high price target for FOLD is $31.00 and the low price target for FOLD is $12.50. There are currently 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of “Hold.”
Amicus Therapeutics has received a consensus rating of Hold. The company’s average rating score is 2.46, and is based on 6 buy ratings, 7 hold ratings, and no sell ratings. According to analysts’ consensus price target of $20.04, Amicus Therapeutics has a forecasted upside of 108.7% from its current price of $9.60. Amicus Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Dividend Strength: Amicus Therapeutics (NASDAQ:FOLD)
Amicus Therapeutics does not currently pay a dividend. Amicus Therapeutics does not have a long track record of dividend growth.
Insiders buying/selling: Amicus Therapeutics (NASDAQ:FOLD)
In the past three months, Amicus Therapeutics insiders have sold 7,120.73% more of their company’s stock than they have bought. Specifically, they have bought $15,000.00 in company stock and sold $1,083,109.00 in company stock. Only 2.50% of the stock of Amicus Therapeutics is held by insiders.
Earnings and Valuation of Amicus Therapeutics (NASDAQ:FOLD
Earnings for Amicus Therapeutics are expected to grow in the coming year, from ($1.03) to ($0.72) per share. The P/E ratio of Amicus Therapeutics is -8.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Amicus Therapeutics is -8.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Amicus Therapeutics has a P/B Ratio of 5.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here